Jay R. Luly, President and CEO at ENANTA PHARMACEUTICALS INC (ENTA), sold 65,875 shares at $125.27 ($8.2M) on 2018-07-06, disclosed to the SEC on 2018-07-09.
Open-market sale of $8.2M ENTA by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $123.81 | 2,977 | $369K | 4.5% |
| 2 | $123.81 | 2,977 | $369K | 4.5% |
| 3 | $124.26 | 12,622 | $1.6M | 19.0% |
| 4 | $124.26 | 12,622 | $1.6M | 19.0% |
| 5 | $125.27 | 7,538 | $944K | 11.5% |
| 6 | $125.27 | 7,538 |
| $944K |
| 11.5% |
| 7 | $126.36 | 7,738 | $978K | 11.9% |
| 8 | $126.36 | 7,738 | $978K | 11.9% |
| 9 | $127.12 | 4,125 | $524K | 6.4% |
| Total | $125.12 avg | 65,875 | $8.2M | 100% |
| Filing → |
| ENTA | SELL | 2024-12-10 | $41K | — | Filing → |
| ENTA | SELL | 2023-12-06 | $139K | — | Filing → |
| ENTA | SELL | 2023-03-14 | $2.5M | — | Filing → |